| Alfuzosin 10 mg once daily increases the chances of successful trial without catheter after acute urinary retention secondary to benign prostate hyperplasia. | |
| | |
MedLine Citation:
|
PMID: 19641358 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
OBJECTIVE: To compare the efficacy of Alfuzosin XL 10 mg once daily for the acute management of acute urinary retention (AUR) with placebo in patients with benign prostatic hyperplasia (BPH) and to determine the predictors that impact this. METHODS: 67 patients presenting with an initial episode of spontaneous AUR secondary to BPH were catheterized and were then prospectively randomized to receiving placebo or 10 mg Alfuzosin XL once daily for 2 days. The allocation and administration of treatment were double-blinded. The primary outcome measure was the rate of successful trial off catheter (TWOC) after 2 days. Clinical characteristics including intravesical prostatic protrusion (IPP) by transabdominal ultrasound were also assessed using uni- and multivariate analysis for their impact on successful TWOC. RESULTS: Three patients withdrew from the study, 2 due to adverse effects of the trial medication. Analysis on an intention-to-treat basis showed a significantly greater proportion of patients in the Alfuzosin XL group (21 of 35 or 60%) had a successful TWOC compared with patients in the placebo group (11 of 32 or 34%) (p = 0.036). Patients with grade 3 IPP (>10 mm) had a significantly lower chance of successful TWOC (p = 0.04) compared to grade 1 (<or=5 mm) and 2 (6-10 mm). It remained a significant independent predictor for failed TWOC after AUR (p = 0.034) on multivariate analysis. CONCLUSION: The administration of Alfuzosin XL prior to TWOC following AUR secondary to BPH increases the chance of successful catheter removal. Patients with IPP >10 mm are more likely to fail TWOC on Alfuzosin XL. |
| | |
Authors:
|
H Y Tiong; M J B Tibung; M Macalalag; M K Li; D Consigliere |
Related Documents
:
|
7538238 - Transurethral resection versus incision of the prostate: a randomized, prospective study. 20850828 - Holmium laser ablation versus photoselective vaporization of prostate less than 60 cc: ... 12084258 - Impact of interventional therapy for benign prostatic hyperplasia on quality of life an... 15062148 - Celecoxib to decrease urinary retention associated with prostate brachytherapy. 14755418 - Photodynamic endometrial ablation for the treatment of dysfunctional uterine bleeding: ... 9556118 - Crusted scabies of the scalp in dermatomyositis patients: three cases treated with oral... |
Publication Detail:
|
Type: Journal Article; Randomized Controlled Trial Date: 2009-07-27 |
Journal Detail:
|
Title: Urologia internationalis Volume: 83 ISSN: 1423-0399 ISO Abbreviation: Urol. Int. Publication Date: 2009 |
Date Detail:
|
Created Date: 2009-07-30 Completed Date: 2009-10-27 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 0417373 Medline TA: Urol Int Country: Switzerland |
Other Details:
|
Languages: eng Pagination: 44-8 Citation Subset: IM |
Copyright Information:
|
Copyright 2009 S. Karger AG, Basel. |
Affiliation:
|
Department of Urology, National University Hospital of Singapore, Singapore. Ho_Yee_Tiong@nuh.com.sg |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Acute Disease Adrenergic alpha-Antagonists / administration & dosage*, adverse effects Aged Double-Blind Method Humans Male Prostatic Hyperplasia / complications Quinazolines / administration & dosage*, adverse effects Urinary Catheterization Urinary Retention / drug therapy*, etiology, therapy |
| Chemical | |
Reg. No./Substance:
|
0/Adrenergic alpha-Antagonists; 0/Quinazolines; 81403-80-7/alfuzosin |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Management outcome of acute urinary retention: model of prediction.
Next Document: Ejaculatory disorders caused by alpha-1 blockers for patients with lower urinary tract symptoms sugg...